PCSK9 Tags LDL Receptors for Degradation Instead of Recycling
Liver-secreted PCSK9 binds LDL receptors, routing them to breakdown.
- Chr 1: PCSK9 gene (liver-secreted protein)
- ~12h: Normal LDLR half-life (recycles ~150 times)
- Shorter: With high PCSK9 (receptor degraded, not reused)
- Higher LDL: Net effect (fewer receptors clear it)
How PCSK9 shortens the receptor cycle
PCSK9 binds LDLR at the cell surface.
Complex is internalized and routed to lysosome.
Receptor is destroyed instead of recycled.
Why this raises blood LDL cholesterol
Fewer surface receptors mean slower LDL uptake.
Circulating LDL cholesterol rises over time.
Genetic PCSK9 variants show this dose effect clearly.
Loss-of-function PCSK9 variants carriers have markedly lower lifetime LDL and cardiovascular risk.
Evolocumab and Alirocumab — Injectable Monoclonal Antibodies
A fully human antibody is injected under the skin on a schedule.
- 2–4 wk: Dosing interval (subcutaneous injection)
- IgG mAb: Drug class (evolocumab / alirocumab)
- Free PCSK9: Target (circulating protein)
- Days: Onset (to peak neutralization)
From injection site to bloodstream
Antibody is absorbed from subcutaneous tissue.
It distributes into plasma over hours to days.
Concentration peaks then slowly declines until next dose.
Why an antibody instead of a pill
PCSK9 is an extracellular target, ideal for antibodies.
High specificity limits off-target binding elsewhere.
Injectable route avoids oral bioavailability problems.
Direct Binding Locks PCSK9 Away From LDL Receptors
The antibody binds PCSK9 tightly, preventing receptor engagement.
- Sub-nM: Binding affinity (high-affinity mAb)
- Steric block: Mechanism (covers LDLR-binding face)
- Falls sharply: Free PCSK9 (as dose rises)
- Cleared: Complex fate (removed from circulation)
Where on PCSK9 the antibody binds
The antibody targets the LDLR-binding domain of PCSK9.
This sterically blocks the PCSK9–LDLR interaction.
Bound PCSK9 can no longer degrade receptors.
Dose-dependent neutralization
Higher antibody dose neutralizes more circulating PCSK9.
Effect scales with drug concentration between doses.
Near-complete blockade is achievable at higher doses.
Neutralizing free PCSK9 is the single mechanistic step driving all downstream benefit.
Unblocked LDL Receptors Return to the Hepatocyte Surface
With PCSK9 blocked, receptors recycle instead of being destroyed.
- Restored: Receptor recycling (default LDLR pathway)
- Rises: Surface density (up to ~2–3×)
- ~150×: Recycle count (per receptor lifetime)
- Days: Timescale (to new steady state)
The default LDL receptor pathway
Without PCSK9, LDLR normally recycles after each use.
Each receptor can clear LDL hundreds of times.
Surface density climbs as degradation stops.
Density scales with antibody exposure
More neutralized PCSK9 means more receptors spared.
Density gains track the dose slider closely.
Effect is reversible if dosing stops.
Additional LDL Lowering on Top of Statin Therapy
More receptors clear LDL faster, adding to statin-driven lowering.
- 50–60%: Added LDL reduction (beyond statin alone)
- Synergistic: Combined with statin (different mechanisms)
- CV benefit: Outcome trials (shown in large RCTs)
- High-risk: Population (statin-inadequate patients)
Why the two mechanisms combine well
Statins upregulate LDLR by lowering cellular cholesterol.
PCSK9 inhibitors prevent that same receptor from being destroyed.
Together they push LDL lower than either alone.
What the outcome trials showed
Large cardiovascular outcome trials tested added mAb therapy.
LDL fell substantially beyond statin-only regimens.
Cardiovascular event rates were reduced in high-risk groups.
Substantial additional LDL lowering translates into measurable reduction in cardiovascular events.